Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Increased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company grew its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 115,765 shares of the company’s stock after buying an additional 1,359 shares during the period. The Manufacturers Life Insurance Company owned about 0.19% of Protagonist Therapeutics worth $5,209,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Farallon Capital Management LLC lifted its stake in Protagonist Therapeutics by 1.8% during the second quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock worth $202,383,000 after purchasing an additional 101,800 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock worth $78,034,000 after purchasing an additional 1,733,662 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 27.6% during the second quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company’s stock worth $43,962,000 after purchasing an additional 274,412 shares during the period. Millennium Management LLC lifted its position in shares of Protagonist Therapeutics by 2,135.6% in the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock worth $33,205,000 after buying an additional 915,418 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Protagonist Therapeutics by 7.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after buying an additional 39,850 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the completion of the transaction, the chief executive officer now directly owns 435,208 shares of the company’s stock, valued at approximately $20,437,367.68. This trade represents a 15.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock in a transaction on Friday, November 15th. The shares were sold at an average price of $40.98, for a total value of $78,107.88. Following the transaction, the insider now owns 46,444 shares in the company, valued at approximately $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 232,066 shares of company stock valued at $10,681,738. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Up 2.7 %

Shares of NASDAQ PTGX opened at $41.68 on Friday. The stock has a market cap of $2.48 billion, a P/E ratio of 15.67 and a beta of 2.18. The firm’s 50-day simple moving average is $44.81 and its 200 day simple moving average is $40.06. Protagonist Therapeutics, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $48.89.

Analyst Ratings Changes

A number of brokerages have issued reports on PTGX. Wedbush reissued an “outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. TD Cowen upgraded Protagonist Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 25th. Truist Financial initiated coverage on Protagonist Therapeutics in a research note on Monday, September 9th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Protagonist Therapeutics has an average rating of “Buy” and a consensus price target of $53.57.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.